LG Chem Partners with UK Biotech LabGenius to Accelerate AI-Driven Antibody Discovery on June 18

According to Chosun Daily, LG Chem signed a joint research agreement with UK biotech LabGenius Therapeutics on June 18 to accelerate AI-driven antibody discovery. The companies will use AI and robotic experiments to speed the discovery of anticancer antibodies and shorten the clinical trial pathway. LabGenius' EVA platform combines active learning with automated functional screening. LG Chem will provide upfront payment and research funding, with potential license-in agreements for antibody candidates to follow.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments